Dr. Reddy’s has launched Supanac (Diclofenac potassium immediate release 50 mg tablets) – a Non-steroidal anti-inflammatory (NSAID) drug that exhibits analgesic, anti-pyretic and anti-inflammatory activities, in India.

Dr. Reddy's Laboratories, an emerging global pharmaceutical company with proven research capabilities from India has launched Supanac (Diclofenac potassium immediate release 50 mg tablets) – a Non-steroidal anti-inflammatory (NSAID) drug that exhibits analgesic, anti-pyretic and anti-inflammatory activities, in India. With this launch it is increasing its offering in the Rs 2700 crore  growing at the rate of 20%.

Supanac is in-licensed from Applied Pharma Research (APR), Switzerland and is used for Acute Pain management. This patented product has been developed by Dynamic Buffered Technology (DBT) making it a superior formulation of Diclofenac, which reaches peak plasma concentration approximately four times faster than Diclofenac enteric coated preparations thereby ensuring faster pain relief. Supanac has been marketed in India for more than 15 years and it is widely used for pain management. Leading brands of Dr. Reddy’s in this segment include Nise and Retoz.